Purpose

The purpose of this study is to determine whether viewing asynchronous movies leads to better visual outcomes in young children with amblyopia than standard-of-care occlusion therapy with an adhesive patch and whether this is associated with better adherence to treatment.

Condition

Eligibility

Eligible Ages
Between 3 Years and 7 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • aged 3-7 years - male and female - strabismic, anisometropic, or combined mechanism amblyopia (visual acuity 0.3-0.8 logMAR) - interocular visual acuity difference ≥0.3 logMAR - wearing glasses (if needed) for a minimum of 8 weeks with no change in visual acuity at 2 visits ≥4 weeks apart - child's ophthalmologist and family willing to forgo standard patching treatment during the study

Exclusion Criteria

  • prematurity ≥8 wk - coexisting ocular or systemic disease - developmental delay - strabismus >5 pd - myopia > -3.00D

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Asynchronous movies
Asynchronous 3D movies
  • Device: Asynchronous 3D movies
    3D movies streamed at home for viewing on a handheld lenticular 3D screen
Active Comparator
Standard-of-care patching with an adhesive patch
Standard-of-care patching with an adhesive patch
  • Device: Patching
    Adhesive patch to cover the fellow eye

Recruiting Locations

Retina Foundation
Dallas, Texas 75241
Contact:
Reed M Jost, MS
214-363-3911
reedjiost@retinafoundation.org

More Details

Status
Recruiting
Sponsor
Retina Foundation of the Southwest

Study Contact

Eileen E Birch, PhD
2143633911
ebirch@retinafoundation.org

Detailed Description

This is a single-site randomized clinical trial to compare treatment of amblyopia by viewing asynchronous movies to standard-of-care occlusion therapy with an adhesive patch. Participants will be referred from local pediatric ophthalmologists. Following informed consent, children will complete baseline testing to confirm eligibility and provide pre-treatment measurements of visual acuity, suppression, stereoacuity, motor skills, self-perception, and quality of life. Eligible children will then be randomly allocated to either patch-free occlusion therapy or standard-of-care occlusion therapy with an adhesive patch. Children will participate in their assigned occlusion therapy at home for 6 weeks (primary outcome). Adherence will be objectively monitored. Vision will be re-assessed at 2 weeks and all tests will be repeated at 6 weeks. The asynchronous movie group will have an option to continue for and additional 2 or 4 weeks (10 weeks total). The standard-of-care occlusion group will be offered the opportunity to use the movie treatment at the 6 week visit through 10 weeks. Children who choose to remain in the study beyond the 6 week primary outcome visit will have vision reassessed at 8 and 10 weeks. The primary analysis will be a comparison of improvement in amblyopic eye visual acuity (baseline-6 weeks) between the movie group and the standard-of-care patching group. Secondary analyses will include comparisons of adherence to each treatment, comparison of the proportion of children in each group with visual acuity ≤0.1 logMAR (recovered) at 6 weeks and 95% CIs, comparisons of changes in extent of suppression, depth of suppression, stereoacuity, motor skills standard scores, self-perception scores, and PedEyeQ domain scores. Associations among hours of treatment, changes in visual acuity, suppression, and stereoacuity, will be explored and modeled for dose-response relationships. In exploratory analyses, we will examine whether there are additional improvements in visual acuity, suppression, or stereoacuity between 6 and 10 weeks for the movie group (8 and 10 weeks means and 95% CIs).

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.